Skip to search formSkip to main contentSkip to account menu

RPC1063

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
The central nervous system is characterized by a high content of sphingolipids and by a high diversity in terms of different… 
2018
2018
Ozanimod (RPC1063) is a specific and potent small molecule modulator of the sphingosine 1-phosphate receptor 1 (S1PR1) and… 
2018
2018
The introduction of oral disease modifying therapies has transformed the treatment landscape for patients with multiple sclerosis… 
Review
2017
Review
2017
Sphingosine 1-phosphate receptor (S1PR) modulators possess a unique mechanism of action in the treatment of multiple sclerosis… 
Highly Cited
2016
Highly Cited
2016
Sphingosine1‐phosphate (S1P) receptors mediate multiple events including lymphocyte trafficking, cardiac function, and… 
Highly Cited
2016
Highly Cited
2016
BACKGROUND Ozanimod (RPC1063) is an oral agonist of the sphingosine-1-phosphate receptor subtypes 1 and 5 that induces peripheral… 
Review
2015
Review
2015
Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease-modifying therapy for multiple… 
2015
2015
Digestive Disease Week (DDW) 2015 will take place in Washington, DC, from May 17 to 19. With more than 400 scientific sessions…